Cornelia Haag-Molkenteller
Directeur Technique/Scientifique/R&D chez UROVANT SCIENCES LTD.
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| James Robinson | M | 54 |
Urovant Sciences, Inc.
 Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 5 ans |
| Sef P. Kurstjens | M | 60 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 10 ans |
| Christine Ocampo | F | 51 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 7 ans |
| James Hindman | M | 63 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 4 ans |
| Shigeyuki Nishinaka | M | 59 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 5 ans |
| Nori Ebersole | F | 60 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 26 ans |
| Ryan Kubota | M | - | - | |
| Ajay Bansal | M | 62 | 5 ans | |
| Myrtle Potter | F | 65 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 ans |
| Pierre Legault | M | 63 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 6 ans |
| Jim Hindman | M | - |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 4 ans |
| Walt Johnston | M | - | 4 ans | |
| Kenton Stewart | M | - | 4 ans | |
| Yuichiro Haruyama | M | - |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 3 ans |
| Alex Thurman | M | 54 | 8 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Paul Bisaro | M | 63 | 5 ans | |
| Scott Giacobello | M | 54 | 7 ans | |
| Brenton Saunders | M | 56 | 6 ans | |
| Keith Katkin | M | 52 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 3 ans |
| David Adam Buchen | M | 59 | 1 ans | |
| Andrew L. Turner | M | 77 | 2 ans | |
| Sigurdur Olafsson | M | 55 | 4 ans | |
| John Kelly | M | 57 | 6 ans | |
| Jonathon Kellerman | M | - | 6 ans | |
| Daphne Karydas | F | 49 | 3 ans | |
| C. Nicholson | M | 68 | 6 ans | |
| Nesli Basgoz | M | 66 | 6 ans | |
| Jirí Michal | M | 71 | 2 ans | |
| Bryan E. Smith | M | 45 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 10 ans |
| Christopher Coughlin | M | 71 | 6 ans | |
| David Hovland | M | - | 8 ans | |
| Joseph H. Boccuzi | M | 77 | 3 ans | |
| Peter John McDonnell | M | 66 | 5 ans | |
| Roger J. Lias | M | 63 | 6 ans | |
| Hafrun Fridriksdottir | M | 62 | 14 ans | |
| Adriane Brown | M | 65 | 3 ans | |
| James H. Bloem | M | 73 | 5 ans | |
| John A. King | M | 74 | 2 ans | |
| Christopher Bodine | M | 68 | 11 ans | |
| Robert Todd Joyce | M | 66 | 1 ans | |
| Patrick O’Sullivan | M | 82 | 5 ans | |
| Michael R. Gallagher | M | 77 | 2 ans | |
| George Frederick Wilkinson | M | 68 | 1 ans | |
| Tamar Howson | F | 75 | 9 ans | |
| Ambrose Bailey | M | 60 | 6 ans | |
| John W. LaRocca | M | 59 | 1 ans | |
| Jonathan Garen | M | 58 | - | |
| Karah Parschauer | F | 46 | 11 ans | |
| Sue-Jean Lin | F | 65 | 26 ans | |
| Lisa Metzner | F | 55 | 3 ans | |
| Megan Schoeps | F | 40 | 2 ans | |
| Abbey Jenkins | F | - | 2 ans | |
| Michael Towers | M | - | 5 ans | |
| David Melnick | M | 72 | - | |
| Herm Cukier | M | 57 | 5 ans | |
| Yao Lee | M | 54 | 4 ans | |
| Daina Schmidt | F | 62 | 9 ans | |
| Ian A. Critchley | M | - | 3 ans | |
| Daniel Motto | M | - | 6 ans | |
| Carlos Campoy | M | 60 | 2 ans | |
| Todd Branning | M | 54 | 3 ans | |
| Sailaja Puttagunta | M | 55 | 1 ans | |
| Dwight Moxie | M | 48 | 5 ans | |
| Kathleen Reape | M | 58 | 1 ans | |
| Matthew Moore | M | 51 | 5 ans | |
| Kathryn DiMarco | F | 57 | 5 ans | |
| David Bharucha | M | 62 | 4 ans | |
| Sanjiv Patel | M | 50 | 11 ans | |
| Michael Dunne | M | 64 | 1 ans | |
| Karen Ling | F | 60 | 5 ans | |
| Gavin R. Corcoran | M | 61 | 4 ans | |
| Matthew Walsh | M | 57 | 2 ans | |
| Charles M. Mayr | M | 67 | 3 ans | |
| James D'Arecca | M | 53 | 7 ans | |
| Jack Michelson | M | 89 | 1 ans | |
| Patrick Spicer | M | - | - | |
| Laurent Fischer | M | 60 | 4 ans | |
| Maria Hilado | F | 59 | 4 ans | |
| Richard Spivey | M | 74 | 5 ans | |
| James O'Brien | M | 57 | 3 ans | |
| William Meury | M | 56 | 6 ans | |
| William Kane | M | 62 | 7 ans | |
| Sigurd Kirk | M | 57 | 8 ans | |
| Dimitrios Angelis | M | 54 | 4 ans | |
| George Brady | M | - | - | |
| Michael Rowe | M | 62 | 6 ans | |
| Pamela Vig | M | 53 | - | |
| Leonard Dove | M | 51 | 2 ans | |
| Enrico Cipro Vanni | M | 73 | - | |
| Elisabeth Sandoval | F | 62 | 23 ans | |
| Michael McFadden | M | 57 |
Urovant Sciences, Inc.
Urovant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Part of Sumitomo Chemical Co., Ltd., Urovant Sciences, Inc. is a pharmaceutical company that prioritizes diversity, equity, and inclusion in rewriting how care is provided in urology. The company is based in Irvine, CA and offers programs to improve patient care, with a current focus on overactive bladder. Urovant Sciences is expanding opportunities to help patients in and beyond, with links to marketed product sites for patients and healthcare professionals, plus patent information. Recently, Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned subsidiaries to form Sumitomo Pharma America, Inc., which will include Urovant Sciences and other subsidiaries. | 1 ans |
| Jeffrey D. Nornhold | M | 58 | 7 ans | |
| Paul Navarre | M | - | - | |
| Eric Lefebvre | M | 60 | 2 ans | |
| Lisa M. DeFrancesco | F | 45 | - | |
| Tina Devries | M | 63 | 1 ans | |
| Robert Stewart | M | 56 | 9 ans | |
| Thomas Nee | M | - | 2 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Irlande | 84 | 85,71% |
| Etats-Unis | 13 | 13,27% |
| Bermudes | 10 | 10,20% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Cornelia Haag-Molkenteller
- Réseau Personnel
